Prosecution Insights
Last updated: November 20, 2026
Application No. 19/295,066

PLANT REGULATORY ELEMENTS AND USES THEREOF

Non-Final OA §102§112§DOUBLEPATENT
Filed
Aug 08, 2025
Priority
Jan 19, 2017 — provisional 62/448,019 +5 more
Examiner
KUMAR, VINOD
Art Unit
1663
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Monsanto Technology LLC
OA Round
1 (Non-Final)
83%
Grant Probability
Favorable
1-2
OA Rounds
10m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 83% — above average
83%
Career Allowance Rate
1198 granted / 1448 resolved
+22.7% vs TC avg
Strong +20% interview lift
Without
With
+20.2%
Interview Lift
resolved cases with interview
Fast prosecutor
2y 1m
Avg Prosecution
36 currently pending
Career history
1478
Total Applications
across all art units

Statute-Specific Performance

§101
6.7%
-33.3% vs TC avg
§103
21.9%
-18.1% vs TC avg
§102
16.4%
-23.6% vs TC avg
§112
48.6%
+8.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1448 resolved cases

Office Action

§102 §112 §DOUBLEPATENT
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Election/Restriction 1. Applicant’s election of Group I, claims 1-15, and the DNA sequence of SEQ ID NO: 11 in the reply filed on September 8, 2026 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)). Claims 1-18 are pending. Claims 16-18 and SEQ ID NOs: 1-10, 12-29 and 43-45 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to nonelected inventions, there being no allowable generic or linking claim. Claims 1-15 in conjunction with the elected SEQ ID NO: 11 are examined on merits in this Office action. This restriction is made FINAL. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i). Information Disclosure Statement 2. Initialed and dated copies of Applicant’s IDS form 1449 filed in the papers of 01/02/2026 and 08/08/2025 are attached to the instant Office action. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statements are being considered by the examiner. Claim Objections 3. Claims 1, 3 and 4 are objected to because of the following informalities: Claims 1, 3 and 4 are objected to because they contain non-elected SEQ ID NOs. Appropriate action is requested. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. 4. Claims 1-15 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for a recombinant DNA molecule comprising the nucleotide sequence of SEQ ID NO: 11 which enhances expression activity of an operably linked promoter, transgenic plant cell, transgenic plant, transgenic progeny, transgenic part of a transgenic plant or transgenic seed comprising said recombinant DNA molecule, does not reasonably provide enablement for (i) DNA sequence of SEQ ID NO: 11 by itself (without operably linked promoter) having enhancer activity (ii) any gene regulatory activity, (iii) a fragment of SEQ ID NO: 11, and (iv) DNA sequences having 85%, 90% or 95% sequence identity to SEQ ID NO: 11. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to practice the invention commensurate in scope with these claims. The claimed invention is not supported by an enabling disclosure taking into account the Wands factors. In re Wands, 858/F.2d 731, 8 USPQ2d 1400 (Fed. Cir. 1988). In re Wands lists a number of factors for determining whether or not undue experimentation would be required by one skilled in the art to make and/or use the invention. These factors are: the quantity of experimentation necessary, the amount of direction or guidance presented, the presence or absence of working examples of the invention, the nature of the invention, the state of the prior art, the relative skill of those in the art, the predictability or unpredictability of the art, and the breadth of the claim. The claims are broadly drawn to a recombinant DNA molecule comprising a DNA sequence with at least 85 percent, 90 percent or 95 sequence identity to SEQ ID NO: 11; a fragment of SEQ ID NO: 11 with gene-regulatory activity, or wherein the DNA sequence is operably linked to a heterologous transcribable DNA molecule, or wherein the DNA sequence comprises gene-regulatory activity, or wherein the heterologous transcribable DNA molecule comprises a gene of agronomic interest, or wherein the gene of agronomic interest confers herbicide tolerance in plants, or wherein the gene of agronomic interest confers pest resistance in plants, or a transgenic plant cell comprising the recombinant DNA molecule, or wherein the DNA sequence is operably linked to a heterologous transcribable DNA molecule in said transgenic plant cell comprising the recombinant DNA molecule, or wherein said transgenic plant cell is a monocotyledonous or dicotyledonous plant cell, a transgenic plant, or part thereof, comprising the recombinant DNA molecule, or a progeny plant of the transgenic plant, or a part thereof, wherein the progeny plant or part thereof comprises the recombinant DNA molecule, or a transgenic seed, wherein the seed comprises the recombinant DNA molecule. The breadth of claims are directed to DNA sequences having at least 85%, 90% or 95% identity to instant SEQ ID NO: 11. The breadth of claims also encompass fragments of unspecified size derived from SEQ ID NO: 11, and exhibiting a gene regulatory activity. The instant specification, however, only provides guidance for how to make and use a nucleic acid sequence of SEQ ID NO: 11 which is a synthetic intron sequence and has enhancer activity when operably linked to a promoter. The specification also teaches for example, that construct of SEQ ID NO: 10 comprising promoter of SEQ ID NO: 5 operably linked to leader sequence SEQ ID NO: 6 and intron sequence of SEQ ID NO: 11 and also operably linked to GUS coding sequence. The specification also teaches transgenic plants transformed with said constructs. These transgenic plants, and seeds derived thereof exhibited GUS activity in transgenic tissues. Transgenic plants transformed with constructs having SEQ ID NO: 11 exhibited increased GUS expression in certain tissues compared to constructs lacking SEQ ID NO: 11. See in particular, examples 3, 4 and 15; tables 3, 4 and 13. The instant specification however, fails to provide guidance on how to make fragment(s) of SEQ ID NO: 11 that functions to have a gene regulatory activity. The instant specification also fails to provide guidance on how to make DNA sequences having 85%, 90% or 95% identity to SEQ ID NO: 11 that exhibit a gene regulatory (enhancer) activity. The instant specification at the paragraph [0087] bridging pages 15 and 16, says: “In plants, the inclusion of some introns in gene constructs leads to increased mRNA and protein accumulation relative to constructs lacking the intron. This effect has been termed “intron mediated enhancement” (IME) of gene expression. Introns known to stimulate expression in plants have been identified in maize genes (e.g., tubA1, Adh1, Sh1, and Ubi1), in rice genes (e.g., tpi) and in dicotyledonous plant genes like those from petunia (e.g., rbcS), potato (e.g., st-ls1) and from Arabidopsis thaliana (e.g., ubq3 and pat1). It has been shown that deletions or mutations within the splice sites of an intron reduce gene expression, indicating that splicing might be needed for IME. However, IME in dicotyledonous plants has been shown by point mutations within the splice sites of the pat1 gene from A. thaliana. Multiple uses of the same intron in one plant have been shown to exhibit disadvantages. In those cases, it is necessary to have a collection of basic control elements for the construction of appropriate recombinant DNA elements. Exemplary introns useful in practicing the present invention are presented as SEQ ID NOs:9, 11, 17, 33 and 41.” The specification does not provide guidance in the specification with respect to making unspecified nucleotide changes in SEQ ID NO: 11 and still exhibit gene regulatory activity (e.g. enhancer activity). Thus, from the guidance in the specification, it would appear that the vast majority of the nucleotides in SEQ ID NO: 11 could be deleted, substituted, added and/or inserted with any other nucleotide. Making nucleotide change(s) in a nucleotide sequence which is capable of having gene regulatory activity, or regulating transcription in a plant is highly unpredictable. While it is known that many nucleotide substitutions, additions or deletions are generally possible in any given nucleic acid sequence (intron) capable of gene regulatory activity in a plant cell, the positions within the promoter or enhancer sequence where such nucleotide changes can be made with a reasonable expectation of success (without abrogating gene regulatory activity) are limited. It was well established in the art at the time the claimed invention was made that changing a single base randomly would abrogate gene regulatory activity. See, for example Kim et al. (Plant Molecular Biology, 24:105-117, 1994, see in particular Tables 2-4) who teach that small alterations in a nos (nopaline synthase) promoter strongly influenced gene regulatory activity. See in particular, page 108, table 1; page 109, table 2. Neither the state of art at the time the invention was made nor Applicant provided guidance as to which region(s) or fragments of SEQ ID NO: 11 should be conserved and which region(s) would tolerate additions, deletions, substitutions and/or insertions of one or more nucleotides without abrogating the gene regulatory activity. The specification fails to provide guidance as to which region(s) of SEQ ID NO: 11 should be conserved and which region(s) would tolerate additions, deletions, and/or substitutions of one or more nucleotides without abrogating the gene regulatory activity when used to express a transcribable polynucleotide molecule in a cell, such as, a plant cell. Neither the state of art nor Applicant provided guidance as to how inoperable embodiments could have been readily eliminated other than random trial and error. In the absence of guidance, making and analyzing nucleotide sequences with a large number of nucleotide changes that have the gene regulatory activity would require undue experimentation. It would also have been highly unpredictable for one skilled in the art to determine how to use variants or fragments of SEQ ID NO: 11 for obtaining gene regulatory activity in a plant. Enhancers, unlike proteins, do not have conservative base or amino acid substitutions. A single nucleotide difference, can abrogate gene regulatory activity. In the absence of guidance, making and analyzing DNA sequences with a large number of nucleotide changes that have the gene regulatory activity in a plant would require undue experimentation. Thus, extensive teachings are required for making DNA comprising a nucleotide sequence having unspecified changes in the nucleotide sequence of SEQ ID NO: 11 that has the gene regulatory activity. The specification does not teach how to use these fragments of SEQ ID NO: 11 or plants comprising them. In the absence of guidance, undue experimentation would have been required at the time the claimed invention was made to determine which sequences are needed in the instantly claimed polynucleotide molecule that are required for gene regulatory activity. See Genentech, Inc. v. Novo Nordisk, A/S, USPQ2d 1001, 1005 (Fed. Cir. 1997), which teaches that “the specification, not the knowledge of one skilled in the art” must supply the enabling aspects of the invention. Claim 1 and claims dependent thereon encompass using SEQ ID NO: 11 by itself or in any gene promoter, leader and terminator sequence combinations to have gene regulatory activity in any cell type. Claim 1 is also encompasses any regulatory molecule which functions to regulate the activity of any gene. The breadth of the phrase "gene regulatory activity" would encompass unspecified type of regulatory molecules, such as, promoter(s), enhancer(s), cis-acting element(s), trans acting element(s), gene suppressing sequence(s), transcript destabilizing sequence(s), antisense sequence(s), miRNAs etc. Furthermore, the phrase “gene regulatory activity" would also encompass any type gene regulatory activity. The state of art related with regulating expression of plant genes by gene regulatory molecules (e.g. enhancers such as introns) is highly unpredictable. For example, Dugdale et al. (Plant Cell Reports, 20:220-226, 2001; see in particular, abstract), teach that the maize adhl intron does not have gene enhancing properties when used with the heterologous BT6.1 promoter. Also see Vain et al. (Plant Cell Reports 15: 489-494, 1996; see in particular, page 489) who teach that monocot introns do not simulate, and often reduce gene expression in dicot species. The state of the art on regulatory polynucleotide molecules teach that plant gene regulatory mechanism is very complex involving core elements, enhancer/regulatory elements of a promoter which interact with activators in a sequence specific manner. See for example Tyagi et al. (Current Science, 80: 161-169, 2001; see in particular, paragraph bridging right column of pg 161 with left column of pg 162) who teach that enhancers can act at a distance in both orientation and position independent manner, and a number coactivators are involved in establishing the final gene regulatory response. As the specification does not provide guidance on unspecified regulatory polynucleotide molecules isolated from diverse sources comprising SEQ ID NO: 11 or fragment(s) thereof nor it provides guidance on the unspecified fragment(s) or "cis element" derived from such polynucleotide molecules, undue experimentation would have been required by one skilled in the art at the time the claimed invention was made to isolate such regulatory molecule(s), cis element(s) or fragment(s) thereof and then test them for unspecified gene regulatory activities. This would not be a routine experimentation for one skilled in the art. Given the claim breath, unpredictability, and lack of guidance as discussed above, undue experimentation would have been required by one skilled in the art to develop and evaluate nucleic acids having SEQ ID NO: 11 or a fragment thereof for a gene regulatory activity. As the specification does not describe the transformation of any plant with said nucleic acids, undue trial and error experimentation would be required to screen through the myriad of nucleic acids encompassed by the claims and plants transformed therewith, to identify those exhibiting a gene regulatory activity, if such plants are even obtainable. Given the breadth of the claims, unpredictability of the art and lack of guidance of the specification, as discussed above, undue experimentation would be required by one skilled in the art to make and use the claimed invention commensurate in scope with the teachings of the specification. 5. Claims 1-15 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. The claims are broadly drawn to a recombinant DNA molecule comprising a DNA sequence with at least 85 percent, 90 percent or 95 sequence identity to SEQ ID NO: 11; a fragment of SEQ ID NO: 11 with gene-regulatory activity, or wherein the DNA sequence is operably linked to a heterologous transcribable DNA molecule, or wherein the DNA sequence comprises gene-regulatory activity, or wherein the heterologous transcribable DNA molecule comprises a gene of agronomic interest, or wherein the gene of agronomic interest confers herbicide tolerance in plants, or wherein the gene of agronomic interest confers pest resistance in plants, or a transgenic plant cell comprising the recombinant DNA molecule, or wherein the DNA sequence is operably linked to a heterologous transcribable DNA molecule in said transgenic plant cell comprising the recombinant DNA molecule, or wherein said transgenic plant cell is a monocotyledonous or dicotyledonous plant cell, a transgenic plant, or part thereof, comprising the recombinant DNA molecule, or a progeny plant of the transgenic plant, or a part thereof, wherein the progeny plant or part thereof comprises the recombinant DNA molecule, or a transgenic seed, wherein the seed comprises the recombinant DNA molecule. The breadth of claims are directed to DNA sequences having at least 85%, 90% or 95% identity to instant SEQ ID NO: 11. The breadth of claims would encompass sequences having unspecified changes in the nucleotide sequence of SEQ ID NO: 11, and exhibiting a gene regulatory activity. The breadth of claims also encompass fragments of unspecified size derived from SEQ ID NO: 11, and exhibiting a gene regulatory activity. Thus breadth of claims would encompass a large genus comprising species of unknown structure and thus their function is either unpredictable or unknown. The specification however, only describes the structure of SEQ ID NO: 11. The specification also describes the function of enhanced promoter activity for SEQ ID NO: 11 in a plant by using it as enhancer element in the promoter of SEQ ID NOs: 5 and 13 (for example). The specification describes that SEQ ID NO: 11 is a synthetic intron sequence and has enhancer activity when operably linked to a promoter. The specification also describes for example, that construct of SEQ ID NO: 10 comprising promoter of SEQ ID NO: 5 operably linked to leader sequence SEQ ID NO: 6 and intron sequence of SEQ ID NO: 11 and also operably linked to GUS coding sequence. The specification also describes transgenic plants transformed with said constructs. These transgenic plants, and seeds derived thereof exhibited GUS activity in transgenic tissues. Transgenic plants transformed with constructs having SEQ ID NO: 11 exhibited increased GUS expression in certain tissues compared to constructs lacking SEQ ID NO: 11. See in particular, examples 3, 4 and 15; tables 3, 4 and 13. The breadth of the phrase “gene regulatory activity” would encompass a genus having unspecified number and types of genes whose activity would regulated by the SEQ ID NO: 11 or a fragment of SEQ ID NO: 11. The specification does not describe structure of said genes ether, and thus their function is unknown. The specification fails to describe representative species of Applicant’s broadly claimed genus. There is no description of the structure required for the recited function, and no description of the necessary and sufficient elements of a gene regulatory activity of sequences having at least 85%, 90% or 95% identity to SEQ ID NO: 11 or fragments derived from SEQ ID NO: 11. The only species described is SEQ ID NO: 11. One of skill in the art would not recognize that Applicant was in possession of the necessary common attributes or features of the genus in view of the disclosed species. Since the disclosure fails to describe the common attributes that identify members of the genus, and because the genus is highly variant, SEQ ID NO: 11 is insufficient to describe the claimed genus. Accordingly, there is lack of adequate description to inform a skilled artisan that applicant was in possession of the claimed invention at the time of filing. See Written Description guidelines published in Federal Register/Vol.66, No. 4/Friday, January 5, 2001/Notices; p. 1099-1111. Given the claim breadth and lack of guidance as discussed above, the specification does not provide written description of the genus broadly claimed. Accordingly, one skilled in the art would not have recognized Applicants to have been in possession of the claimed invention at the time of filing. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. 6. Claims 1-2, and 5-15 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Boukharov et al. (US Patent Publication No. US2007/0020621 A1, Published January 25, 2007). Boukharov et al. disclose a recombinant molecules comprising DNA sequence(s) having gene regulatory activity (e.g. promoter activity). The reference further discloses making transgenic plants and seeds comprising said recombinant molecules operably linked to a transcribable polynucleotide encoding a polypeptide of agronomic interest, and wherein said polypeptide is a herbicide tolerance (glyphosate resistant EPSPS) or disease resistant protein, or wherein said transgenic plant is corn, rice, soybean or canola. See in particular, claims 1-8, 10, 18-24, 26, 29, 34; page 8, paragraphs 0077-0079; page 12, paragraphs 0117-0127; page 13, paragraphs 0128-0139; page 20; SEQ ID NO: 55335. This rejection is made because of the following reasons: (i) the recitation “a fragment of SEQ ID NO: 11” with gene regulatory activity reads on any DNA molecule having any type gene regulatory activity (including promoter activity, for example). (ii) While the instant specification provides some description regarding promoter fragment(s), however since instant SEQ ID NO: 11 is an enhancer (not a promoter, emphasis added), and the instant specification fails to define enhancer fragments of SEQ ID NO: 11 with enhancer activity of SEQ ID NO: 11. In the absence of guidance, the recitation “a fragment of SEQ ID NO: 11” with gene regulatory activity would read on any DNA molecule with any gene regulatory activity, including promoter activity. Accordingly, Boukharov et al. anticipated the claimed invention. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. 7. Claims 1-15 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 2, 6, 8, 11, 12, 22, 23, 28, 50, 51, 55 and 66 of copending Application No. 18/306,581 (‘581 thereafter). Although the claims at issue are not identical, they are not patentably distinct from each other because SEQ ID NO: 9 of copending ‘581 is having 100% identity to instant SEQ ID NO: 11. A DNA construct, plant cell, plant, commodity product, amplicom of copending ‘581 are encompassed by the instant recombinant DNA molecule, transgenic plant cell, transgenic plant , transgenic progeny or transgenic seed because they all comprise instant SEQ ID NO: 11 having 100% identity to copending SEQ ID NO: 9. The property of gene regulatory activity of copending ‘581 SEQ ID NO: 9 would be inherent characteristics, unless Applicant provides evidence to contrary. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Conclusions 8. Claims 1-15 are rejected. Contact Information Any inquiry concerning this communication or earlier communications from the examiner should be directed to Vinod Kumar whose telephone number is (571) 272-4445. The examiner can normally be reached on 8.30 a.m. to 5.00 pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Amjad A. Abraham can be reached on (571) 270-7058 The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA). /VINOD KUMAR/ Primary Examiner, Art Unit 1663
Read full office action

Prosecution Timeline

Aug 08, 2025
Application Filed
Nov 13, 2026
Non-Final Rejection mailed — §102, §112, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12787964
PEANUT VARIETY 'ARNIE'
2y 6m to grant Granted Nov 10, 2026
Patent 12757846
CANNABIS PLANT NAMED 'LPA004'
4y 8m to grant Granted Oct 13, 2026
Patent 12757861
TOMATO VARIETY NUN 00327 TOP
2y 2m to grant Granted Oct 13, 2026
Patent 12753413
RNA GUIDE GENOME EDITING IN CITRUS USING CRISPR-RIBONUCLEOPROTEIN COMPLEXES
4y 8m to grant Granted Oct 06, 2026
Patent 12751394
SOYBEAN VARIETY
3y 8m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
83%
Grant Probability
99%
With Interview (+20.2%)
2y 1m (~10m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1448 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month